TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Tom Rossi, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the sixth annual Bloom Burton & Co. Healthcare Investor Conference. Mr. Rossi’s address will take place at the Sheraton Centre Toronto Hotel on May 2, 2017 at 4:00 p.m. Eastern Time.
The 2017 Bloom Burton & Co. Healthcare Investor Conference brings together Canadian, U.S. and European investors interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from approximately 60 premier Canadian publicly traded and private healthcare companies through presentations, panel discussions, and private one-on-one meetings.
Acerus Pharmaceuticals Corporation is a fully-integrated, Canadian specialty pharmaceutical company engaged in the development, manufacture, marketing and distribution of innovative, branded products in Men’s and Women’s Health. Acerus’ shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.
Notice regarding forward-looking statements
Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 7, 2017 that is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.